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SYNOPSIS 
Sclerostin is an extracellular negative regulator of bone formation that is a recognised 
therapeutic target for osteoporosis therapy. Here, we perform DNA aptamer selection 
against sclerostin, then characterise aptamer-sclerostin binding and ability to inhibit 
sclerostin function in cell culture. We show that a selected DNA aptamer was highly 
selective for binding to sclerostin with affinities in the nanomolar range as determined by 
solid-phase assays and by isothermal titration calorimetry. Binding between sclerostin 
and the aptamer was exothermic and enthalpically driven. Circular dichroism confirmed 
that the aptamer had temperature-dependent parallel G-quadruplex characteristics. The 
aptamer was stabilised with 3' inverted thymidine to investigate efficacy at inhibiting 
sclerostin function in cell culture. The stabilised DNA aptamer showed potent and 
specific dose-dependent inhibition of sclerostin’s antagonistic effect on Wnt activity 
using a reporter assay. Taken together, these studies present an alternative approach to 
inhibiting sclerostin function with therapeutic potential.  
 
 
INTRODUCTION 
 
Sclerostin is an extracellular protein secreted by osteocytes that acts to negatively 
regulate bone formation [1, 2]. Loss of function mutations in the gene coding for 
sclerostin, SOST, result in the congenital disease sclerosteosis, characterised by strong 
and dense bone [1-4]. As such, sclerostin has become a key target in the development of 
new therapeutics for the treatment of osteoporosis, and significant progress has been 
made in recent years with monoclonal antibodies that inhibit sclerostin function that are 
now in clinical trials [5-8].   
 
Sclerostin is a member of the cystine-knot family including DAN, Cerberus, 
Caronte and Dante, often known as the DAN protein family. Typically these proteins act 
by binding to bone morphogenetic protein (BMP) and antagonising their functions [9, 10]. 
Whilst sclerostin was observed to bind to BMPs, it is most likely that sclerostin mainly 
acts by binding directly to low density lipoprotein receptor-related protein 4, 5 and 6 
(LRP 4/5/6), thereby antagonising canonical Wnt signaling [11-14]. Frizzled and LRP 5/6 
are receptors for transduction of canonical Wnt signaling leading to stabilisation of β-
catenin and regulation of gene transcription by lymphoid enhancing factor (LEF1) and T-
cell factors (TCF) [15]. Defects in this signaling pathway have been frequently 
implicated in congenital skeletal diseases, for example loss of function mutations in 
LRP5 are responsible for human osteoporis-pseudoglioma syndrome and gain of function 
mutations result in a high bone mass phenotype [16, 17].   
 
As the most common treatments for osteoporosis such as oral bisphosphonates are 
antiresorptive rather than anabolic, sclerostin was proposed to be a potentially superior 
therapeutic target. Monoclonal antibodies against sclerostin showed complete reversal of 
oestrogen deficiency-induced bone loss in a mouse model [18], and were able to inhibit 
colitis in a mouse model of chronic colitis [19]. Dose-dependent increases in bone 
formation, bone mineral density and bone strength were observed in a cynomolgus 
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monkey study [20]. In rats, monoclonal antibodies showed bone anabolic effects at bone 
marrow sites [21], and were also shown to enhance metaphyseal bone healing [22]. The 
first human study using a sclerostin monoclonal antibody showed general safety and 
tolerability with increases in a number of bone formation markers [7], and clinical trials 
with regards to efficacy for increased bone formation are ongoing [23].  
 
Whilst it is now clear that sclerostin is a particularly promising target for 
increasing bone formation, there are a number of competing strategies, besides 
monoclonal antibodies, that might be used to inhibit sclerostin function [24]. Nucleic acid 
aptamers selected by in vitro evolution are one alternative approach that have similar 
affinities and specificities to monoclonal antibodies, with potential benefits of scalable 
and modifiable chemical synthesis, small in size and low immunogenicity [25-27]. 
Indeed, in the recent human sclerostin monoclonal antibody study, six subjects in the 
higher dose groups did develop neutralising antibodies against the therapy [7]. Aptamers 
have been clinically proven by pegaptanib (marketed as Macugen), an aptamer-based 
drug used in the treatment of age-related macular degeneration [28] that targets the 
extracellular protein VEGF thereby inhibiting its interaction with its receptors VEGFR1 
and VEGFR2 [29].  
 
In an effort to identify DNA-aptamer inhibitors of sclerostin, we have screened a 
DNA aptamer library with a 30-nt variable region. Using this approach, we identified a 
family of parallel G quadruplex aptamers that potently and specifically bind to sclerostin 
by independent assays. After stabilisation, one aptamer showed dose-response potent 
inhibition of sclerostin-mediated antagonism of Wnt signaling in cell culture.  
 
EXPERIMENTAL  
Source of DNA and cloning. The cDNA of SOST was obtained form Mus musculus 6 
days neonate head cDNA, clone: 5430411E23 (RIKEN; Japan). The coding region of 
SOST was amplified by PCR, using TaKaRa LA taq polymerase (RR002M; TaKaRa) 
with the forward primer 5'-
GTATGTATGAATTCATGCATGCAGCCCTCACTAGCCCC-3' and the reverse primer 
5'-GTATGTATCTCGAGCTAGTAGGCGTTCTCCAGCT-3'. The PCR product was gel 
purified, digested with EcoR1/XhoI and ligated with a similarly digested pGEX-4T1 
vector to make the plasmid pGEX-SOST. 
Expression and purification of sclerostin. 2 litres of LB broth supplemented with 
ampicillin (50 μg/ml) were inoculated with saturated pGEX-SOST/BL21 (DE3) culture 
(1/1000 dilution) and grown at 37°C until A600 = 0.6. Protein expression was induced by 
addition of isopropyl-1-thio-β-D-galactopyranoside (0.25 mM), and cultures were 
incubated at 25 °C for 4 h. After cooling to 4 °C, the cells were harvested by 
centrifugation and resuspended in buffer A: phosphate buffer saline (PBS; pH 7.4) with 
protease inhibitors (Complete, Roche Applied Science), 1 g of wet cell pellet/5 ml of 
buffer). Cells were lysed by sonication (Sonics VibraCell, microtip, 30% power for 10 
min (4 s on, 9.9 s off) with ice cooling) and then centrifuged (30 min, 30,000 × g), and 
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the supernatant was filtered (Corning syringe filter, 0.25 μm) and then applied to 5 ml 
GSTrap HP columns (GE Life Sciences). The 5-ml column was washed with 40 ml of 
buffer A, then 15 ml Buffer B (50 mM Tris-HCl, pH 8.0, 10 mM reduced glutathione 
(Calbiochem) to elute the protein. Pure fractions (by SDS-PAGE) were combined, 
dialysed against PBS and 5 mM β-mercaptoethanol and stored at 4 °C for short term or 
frozen at –80°C with 20% glycerol for long term storage. 
SELEX. The selection of sclerostin binding aptamers relied on magnetic separation with 
the GST-sclerostin that was immobilised on the glutathione sepharose magnetic beads. 
The starting point of the selection process was a random degenerate ssDNA library 
(SelexApt) that was chemically synthesized and HPLC purified. (SelexApt: 5'-CCG TAA 
TAC GAC TCA CTA TAG GGG AGC TCG GTA CCG AAT TC-(N30)-AAG CTT 
TGC AGA GAG GAT CCT T-3'). Primers that anneal to the 5'- and 3'-sequences 
flanking the degenerate region of SelexApt used during the selection and cloning were: 
SelexF , 5'-CCG TAA TAC GAC TCA CTA TAG GGG AGC TCG GTA CCG AAT 
TC-3'; SelexR , 5'-AAG GAT CCT CTC TGC AAA GCT T-3'; in non-biotinylated and 
5'-biotinylated forms, respectively (HPLC purified). Iterative rounds of aptamer selection 
and amplification during the SELEX process were modified from previous protocols [30, 
31]. 1 nmol of DNA library was incubated with GST-sclerostin immobilised on GST 
magnetic beads in PBS for 30 min at room temperature.  The unbound DNA was 
separated and removed by washing with PBS.  The bound sequences were eluted with 
PBS containing 10 mM reduced glutathione (GSH) and PCR amplified using biotinylated 
primers. 90 μl of the PCR reaction product containing enriched biotinylated double 
stranded DNA was equilibrated with 23 μl of 5 M NaCl and 1 mg of M-280 streptavidin 
magnetic beads (Dynal) for 10 min. Non-biotinylated single-stranded DNA was 
recovered and dissociated from the immobilized complementary biotinylated strand using 
50 μl of 100 mM NaOH for 5 min. 15 cycles were performed with counter selection using 
immobilised GST magnetic beads at round 3, 6, 9 and 12.  During the last round of 
SELEX, the recovered DNA molecules were PCR amplified using non-biotinylated 
primers and cloned into pCR-Blunt II TOPO vectors (Invitrogen) and sequenced. 
Multiple sequence alignment was performed by clustalW2 [32]. 
Aptamer-enzyme linked binding assay. An enzyme-linked assay to determine binding 
of biotinylated aptamers to sclerostin was modified from previous protocols [31, 33]. 96 
well plates prepacked with glutathione sepharose media (GE healthcare) were coated 
with 500 ng purified proteins (GST-sclerostin or GST) in 200 μl coating buffer (50 mM 
Tris-Cl pH 8.5, 100 mM NaCl and 100 mM KCl) for 1.5 hr at room temperature. The 
wells were washed 4 times with coating buffer. 3' biotinylated oligodeoxynucleotides 
(Scl 1 to 4 aptamers (Figure 2), thrombin binding aptamer: 5'-GGTTGGTGTGGTTGG-3' 
and oligodeoxynucleotide 35-mer random sequence: 5'-
GAAGGCCGTTCTCAGTGAACAACAAAAACTGCTAG-3') were heated to 90°C and 
then cooled slowly to room temperature. 50 nM aptamers were incubated with protein in 
the 96 well plate overnight at 4°C shaking gently. Wells were washed 6 times with 200 μl 
of coating buffer for each wash 10 min on a plate vortex. Streptavidin horseradish 
perioxidase (Molecular Probes) was diluted 1:2000 in buffer and 200 μl aliquots applied 
to each well. Strips were incubated for 30 min at room temperature and washed again as 
described above. Then, 150 μl of Turbo- 3,3´,5,5´-tetramethylbenzidine (TMB) (Pierce) 
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was added to each well and incubated for 20 min at room temperature in the dark. The 
reaction was quenched by addition of 150 μl of 1M H2SO4 and the protein bound 
aptamer-streptavidin complexes were quantified by determining the absorbance at 450 
nm using SpectraMax Plus (Molecular Devices).  
Isothermal Titration Calorimetry: The binding affinities and binding enthalpies of the 
aptamers to GST-sclerostin and GST were measured by ITC (MicroCal VP-ITC, 
MicroCal Inc. Northampton, MA). In a typical ITC experiment, 15 μM GST-sclerostin or 
20 μM GST was loaded into the cell with 200 μM aptamers or random sequence in the 
titrating syringe. GST-sclerostin and GST were dialysed into the PBS buffer containing 
β-mercaptoethanol using SnakeSkin Dialysis tubing (Pierce) with a MWCO of 10,000. 
Aptamers used were weighed out as solids and dissolved into the buffer used for protein 
dialysis. The titration experiments were performed at 25°C with an initial 0.2 μl injection, 
followed by thirty 1.2 μl injections. The spacing between injections was 200 s. The 
stirring speed during the titration was 900 rpm. Data were analysed using MicroCal 
Origin software by fitting to a single-site binding model. Correction for the enthalpy of 
ligand linear fit from the last three data points of the titration, after the interaction had 
reached saturation.   
Circular Dichroism: Oligonucleotides (10 μM) were resuspended in PBS or Tris-HCl 
(10 mM, pH 7.5) buffer that contained KCl or NaCl. Samples were heated at 90°C for 5 
min, followed by gradual cooling to room temperature. CD spectra were collected on a 
JASCO J810 spectropolarimeter (JASCO, MD, USA) equipped with a water-jacketed cell 
holder at 310nm – 210nm, by using 4 scans at 100 nm min-1, 1 s response time, 1 nm 
bandwidth. Quartz cells with an optical path length of 1 mm were used for the 
measurement. The scans of the buffer alone were substracted from the average scans for 
the sample. CD melting curves obtained at wavelength 260 nm allowed an estimation of 
melting temperature, Tm, the mid-point temperature of the unfolding process. 
Stability of aptamers in cells: 1 μM of Scl 2 and 3' inverted thymidine modified Scl 2 
aptamers were added to MC3T3-E1 cells at 80% confluency. Cells were grown in 6 well 
plates and with 2 ml complete medium (minimal essential media (α-MEM), 
supplemented with 5% FBS, penicillin/Streptomycin and fungizone) at 37°C 
supplemented with 5% CO2. At time point indicated, 10 μl of medium was loaded onto 
urea-PAGE for electrophoresis. Gels were stained with 1:10000 Sybr Gold (Invitrogen) 
for 20 min and images were taken under UV. 
T-cell factor luciferase reporter assay: MC3T3-E1 cells were seeded in 24-well plates 
and transiently transfected with either 100 ng of TOP-Wnt induced luciferase plasmid or 
FOP (control plasmid) using Lipofectamine reagent. Wnt3a (800 ng), sclerostin (800 ng) 
expression vectors were co-transfected when needed. 10 ng of Renilla luciferase vector 
was co-transfected (pRL-SV40; Promega) to correct for transfection efficiency. 6 hr post-
transfection, medium (α-MEM, supplemented with 5% FBS) were changed to antibiotics 
containing medium supplemented with the indicated concentration of aptamers and 
incubated for a further 24 hr. Cells were lysed with 100 μl of passive lysis buffer and 20 
μl was used for analyses. Luciferase assays were performed using Dual-Luciferase 
Reported system (TM040; Promega) according to the manufacturer’s protocol. 
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RESULTS 
 
Selection of DNA aptamers binding to sclerostin. To identify novel DNA aptamers that 
bind to sclerostin, a glutathione sepharose magnetic bead-based selection procedure using 
immobilised GST-sclerostin was employed. A single stranded DNA library containing a 
30-nt random core sequence was passed through the immobilised GST-sclerostin on the 
beads, then binding nucleic acids were eluted with reduced glutathione. Non-specifically 
bound aptamers were eliminated during a counter-selection step using the magnetic beads 
bound to GST (Figure 1). Single-stranded DNA pool was recovered by streptavidin-
magnetic bead purification. Enrichment of a pool that specifically bound to the sclerostin 
was observed after 15 rounds of aptamer selection. We sequenced 30 individual aptamer 
clones, and observed that 90% of the selected sequences belonged to four related 
guanosine rich sequences (Figure 2). Notably, aptamers Scl 1 and Scl 2 were dominant 
sequences that accounted for 80% of the total pool. A high level of sequence homology 
was observed, with a conserved motif present in almost all clones at approximately the 
same location in the random region (5'-GGXGGXXGGXTGGG-3'). This stretch of 
nucleotides may be folded into an unusual guanosine quadruplex structure based on the 
guanine quartet, which should contribute substantial stability to the overall structure [34].    
 
Binding of selected aptamers to sclerostin. To make an initial measurement of the 
relative binding affinities of the aptamers to sclerostin, we employed an enzyme-linked 
solid phase assay whereby the GST-sclerostin was immobilised on a plate then 
biotinylated aptamers were bound at different concentrations and quantified by enzyme-
linked immunoassay [31, 33]. We observed that all the sclerostin aptamers Scl 1-4 bound 
to GST-sclerostin whilst they did not bind to GST alone as a control (Figure 3). The GST 
control showed that our counter-selection strategy of using immobilised GST during the 
selection was effective in removing aptamers that might recognise GST. Scl 3 appeared 
to bind slightly less potently than the other three aptamers: Scl 1, Scl 2 and Scl 4. 
Furthermore, the established thrombin binding aptamer was used as a second control for 
non-specific binding of G quadruplex aptamers to sclerostin and no binding was observed. 
We therefore concluded that the aptamers specifically bound to GST-sclerostin without 
binding to GST. The concentrations used in the experiment suggested nanomolar affinity 
but as this was an immobilised assay we subsequently followed this up with isothermal 
titration calorimetry to accurately measure the binding affinity in solution. 
 
Aptamer stabilisation and inhibition of sclerostin function in mammalian cells. 
Natural phosphodiester oligonucleotides are susceptible to degradation by nucleases, and 
thus would be unsuitable for use in cell studies. Capping the 3' end is one commonly used 
approach to block 3' to 5' exonuclease attack. Therefore, the stability of sclerostin 
aptamer (Scl 2) modified with 3' inverted thymidine (3'-InT) was evaluated in MC3T3-E1 
cells that were supplemented with 5% FBS (Figure 4A). MC3T3-E1 cells are an 
osteoblastic cell line that express the receptors upon which sclerostin exert its effect. 
Without any modifications, aptamers were quickly degraded by nuclease in serum as 
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observed by the smear (Figure 4A). However, the modified 3' inverted thymidine 
aptamers were stable with apparent levels unchanged after 28 hr, suggesting that 3' 
inverted thymidine capping is a suitable approach for the stabilisation of sclerostin 
aptamers.  
To investigate whether the selected 3' InT modified aptamers are able to inhibit 
sclerostin function in cell culture, we employed lymphoid enhancer factor/T-cell factor 
(LEF/TCF) luciferase reporter assay to study the effects of aptamers on Wnt mediated 
activity in osteoblast MC3T3-E1 cells. MC3T3-E1 cells do not endogenously express 
sclerostin but they do express the receptors and the signalling pathway downstream from 
sclerostin. Both LEF and TCF are nuclear transducers of an activated canonical Wnt/β-
catenin pathway as they interact with β-catenin (Figure 4B). TOP flash luciferase reporter 
contains three Wnt-specific binding sites for TCF/LEF transcription factors and the 
firefly luciferase reporter (Fluc) under the control of herpes simplex virus thymidine 
kinase; whilst the FOP flash construct is identical to the TOP construct with three TCF 
binding sites that are mutated and thus serves as a negative control. The luciferase gene is 
driven by the promoter which is specifically activated by the binding of β-catenin through 
the activation of Wnt.   
The Wnt pathway only becomes active when Wnt3a is expressed (Figure 4C, bars 
1 and 2). As expected when both sclerostin and Wnt3a are expressed then sclerostin 
antagonises the Wnt pathway (Figure 4C, bar 3). The impact of each aptamer was then 
determined by adding the 3' inverted thymidine modified aptamers at 1.5 μM 
concentration 6 hours post-transfection, then determining the luciferase activity after a 
further 24 hours incubation. It was clear that Scl 2 potently inhibited sclerostin’s 
antagonist effect on Wnt signalling (Figure 4C, bar 5) whilst the other three aptamers Scl 
1, Scl 3 and Scl 4 were not able to inhibit sclerostin (Figure 4C, bars 4, 6, 7). In further 
controls, the aptamers did not have any effect on luciferase activity in the absence of 
Wnt3a and/or SOST, and nor did SOST have any effect in the absence of Wnt3a. Finally, 
we determined whether the 3' inverted thymidine Scl 2 aptamer showed a dose-response 
by investigating its impact at varying concentrations from 0.1 μM to 1.5 μM. A clear dose 
response was observed (Figure 4D) with increasing concentrations of Scl 2 sclerostin 
inverted thymidine modified aptamer with an IC50 of approximately 900 nM.  
 
Sclerostin-Scl 2 aptamer interaction analysis by isothermal titration calorimetry. 
Our previous binding experiment showed all sclerostin aptamers to have high binding 
affinity for sclerostin, but concomitant experiments in mammalian cell culture indicated 
that Scl 2 was the most promising of these aptamers. We performed isothermal titration 
calorimetry (ITC) to compare the sclerostin aptamers to understand the relationship 
between affinity and potency against sclerostin. For the ITC experiment, the sclerostin 
aptamers were titrated into the GST-sclerostin and the heat changes were observed 
(Figure 5A). Binding isotherms (typical data shown for Scl2 binding to sclerostin) for the 
interaction showed an exothermic binding event (Figure 5A), and controls showed that a 
random DNA sequence was unable to bind GST-sclerostin (Figure 5B) and that the 
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aptamer was binding to sclerostin and not the GST domain of the GST-sclerostin fusion 
(Figure 5C).  
Our results showed that the binding stoichiometry (n) was 0.91 ± 0.02, indicating that 
~0.91 molecules of Scl 2 aptamer bind per one sclerostin molecule. Binding of Scl 2 
aptamer to sclerostin was exothermic. Binding is enthalpically favored but entropically 
opposed (Table 1). The large enthalpic contribution to the ΔG of binding between 
aptamers and GST-sclerostin implies the formation of hydrogen bonds and electrostatic 
interactions.  
The thermodynamic parameters of sclerostin aptamers 1 to 4 and Scl 2 3' inverted 
thymidine aptamer binding to GST-SOST derived from ITC are summarised (Table 1). 
All aptamers bound to sclerostin with affinities with a KD ranging from 0.2-2.1 μM. Scl 2 
aptamers and its inverted thymidine modified form which showed potency in mammalian 
cell culture bound to GST-SOST more strongly than Scl 1 and Scl 3. Consistent with the 
previous enzyme-linked binding assay, Scl 4 also bound tightly to GST-SOST. Although 
Scl 4 has higher binding affinity than Scl 2, Scl 4 did not have an inhibitory effect on 
sclerostin in cell culture. Considering that Scl 2 has a 5’ “tail” whilst Scl 4 has a 3’ “tail”, 
this indicates that the 5’ “tail” on Scl 2 may also be important for efficacy in cell culture.  
Biophysical properties of sclerostin aptamers by circular dichroism. To characterise 
the secondary structure of the sclerostin aptamers, we employed circular dichroism to 
experimentally investigate whether G-quadruplex structure was formed. In the CD 
spectra, all sclerostin aptamers showed a positive maximum peak near 265 nm in PBS 
(Figure 6A). A peak at 265 nm is spectroscopic criteria for aptamers to have parallel G-
quadruplex structure [34]. Dependence of G-quadruplex formation on metal ion 
coordination, particularly potassium ions, has been previously reported [35]. The Scl 2 
aptamers in Na+ and K+ showed similar CD spectra. With a decrease in K+ concentration 
(100mM to 1mM), the ellipticity of the 265 nm peaks was almost the same. However, the 
extent of G-quadruplex formation was slightly affected in the absence of potassium ions 
(Figure 6B). Furthermore, we determined the thermal stability of the G-quadruplex 
structure of aptamer Scl 2 by observing circular dichroism under varying temperature, 
thus determining the Tm value of aptamer Scl 2 to be 75°C (Figure 6C). This suggested 
that the structure is stable and suitable for application in the cellular environment. 
 
 
DISCUSSION 
This study identifies a DNA aptamer that binds specifically to sclerostin with nanomolar 
affinity. The aptamer had parallel G quadruplex characteristics, was thermally stable, and 
could be stabilised to nuclease activity by 3' inverted thymidine capping. The stabilised 
aptamer potently inhibited sclerostin’s antagonistic effect on Wnt signalling in a cell 
culture assay showing a dose-response with an IC50 of 900 nM.  
With particular relevance to this study, the NMR structure of sclerostin was 
published by two independent groups recently [8, 36]. One study revealed that sclerostin 
has a binding site for heparin, and that the antibody binding site and heparin binding site 
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on sclerostin had minimal overlap [8]. The second study highlighted the unusual 
abundance of positively charged residues resulting in a basic protein (pIcalc 9.6) [36]. 
Calculation of the electrostatic potential between sclerostin and LRP5 propellor revealed 
the positively charged putative binding site of sclerostin bound directly to the highly 
negatively charged binding site on LRP5 [36]. In the selection of aptamers in this study, 
it is likely that negatively charged phosphodiester backbone in the aptamers would be 
selected against the major positively charged surface on sclerostin. This would also be 
consistent with the highly enthalpic contributions observed in our ITC experiments in the 
interaction between the sclerostin and the aptamer. Thus, the Scl 2 aptamer may act as an 
LRP 5 mimic and directly compete for binding with LRP5. Alternatively, the aptamers 
may mimic heparin and compete for heparin binding, thus disrupting the heparin-
mediated localisation of sclerostin to the cell surface [8]. Further experiments would be 
required to test these alternate hypotheses. As the antibody binding site had little overlap 
with the heparin binding site [8], it is possible that the aptamer binds at a site distinct 
from the antibody binding site, thus suggesting that an aptamer/antibody cocktail may 
have a synergistic effect on inhibiting sclerostin function.  
The relative potencies of the established monoclonal antibodies compared to the 
aptamer in this study can be compared. A similar assay was performed in MC3T3-E1 
cells to investigate the potency of antibodies inhibiting sclerostin function using an 
antibody concentration of 100 μg/ml, to totally inhibit sclerostin function although the 
IC50 was not disclosed [8].  In our experiments we used a sclerostin aptamer 
concentration of 1.5 μM, equivalent to 14.2 μg/ml, to inhibit sclerostin, so the potency in 
cell culture could be considered to be in a similar range. As far as we are aware, the 
dissociation constants of the specific monoclonal antibodies that went into animal and 
human trials have not been disclosed. However, monoclonal antibodies against the N- 
terminal and C-terminal regions of human and mouse sclerostin peptides in another study 
bound tighter with KD of 3 nM for an antibody against the N-terminal peptide and 8 nM 
for an antibody against the C-terminal peptide [37], compared to 700 nM for Scl 2 herein. 
Nevertheless, further optimization and modification of Scl 2 would be likely to increase 
its affinity several-fold as has been performed in other aptamer studies [25]. 
Targeting sclerostin to stimulate bone growth is now established as an approach 
with significant therapeutic potential given the pioneering studies using monoclonal 
antibodies [24]. One potential drawback of targeting Wnt signalling is that the Wnt 
signalling is not an on-off process [24]. If the Wnt signalling is constitutively activated, 
cancer may result, and conversely if Wnt signalling is fully inhibited, osteoporosis and 
heart failure may result [24]. This suggests that fine-tuning by using, for example, 
aptamer antidotes based on complementary base-pairing [38, 39] could provide an 
approach to control anti-sclerostin activity which would not be available for antibody-
based therapy and small molecules. Nevertheless, aptamers can have drawbacks in that 
their pharmacokinetic and systemic properties are variable and can be unpredictable, and 
their therapeutic use is less established than antibodies [25]. Further research will be 
required to assess aptamer efficacy in animal models to investigate how aptamer-based 
targeting compares to antibody-based targeting, and whether there is any potential for a 
synergistic approach. Further optimisation and modification of this particular aptamer 
may lead to the development of a new bone-forming agent.  
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Aptamers KD (μM) ∆H (kcal/mol) T∆S (kcal/mol) ∆G (kcal/mol) 
Scl 1 1.34 ± 0.33 -27.1 ± 2.1 -19.1 ± 2.2 -8.0 ± 0.2 
Scl 2 0.67 ± 0.08 -18.6 ± 2.1 -10.2 ± 2.2 -8.4 ± 0.1 
Scl 3 2.07 ± 0.68 -24.3 ± 5.9 -16.6 ± 6.1 -7.7 ± 0.2 
Scl 4 0.20 ± 0.05 -25.2 ± 2.1 -16.1 ± 2.2 -9.1 ± 0.1 
Scl 2 InT 0.41 ± 0.03 -18.3 ± 1.7 -8.2 ± 1.9 -10.1 ± 0.2 
 
Table 1: Experimentally determined thermodynamic parameters for sclerostin aptamers 
binding to GST-sclerostin derived from ITC measurements at 25 °C. 
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FIGURE LEGENDS 
 
Figure 1. A schematic drawing showing the method used for sclerostin aptamer 
selection. GST-tagged sclerostin was immobilised on magnetic beads. The library was 
incubated with the target beads for binding. Unbound oligonucleotides were washed 
away, and the bound ones were eluted with the target by reduced glutathione. The 
selected binders were amplified by PCR by using biotinylated primers. ssDNA was 
subsequently purified from the PCR product using streptavidin coated magnetic beads, 
resulting in an enriched DNA pool, which was used in the next SELEX round. After the 
last round, the selected aptamers were cloned, sequenced and characterised. Counter 
selections were performed using GST immobilized magnetic beads. 
Figure 2. Aptamer selection results. Sequences of the aptamers that were isolated from 
the ssDNA pool after 15 rounds of selection against GST-sclerostin. Conserved 
nucleotides are marked by an asterisk.  
Figure 3. Determination of relative binding strength of aptamers against sclerostin 
using an aptamer enzyme-linked assay. Combinations of sclerostin aptamers, thrombin 
binding aptamers, GST-sclerostin and GST protein (indicated by plus signs below the 
graph) were evaluated for their binding activity and cross-reactivity. Data shown are the 
mean values of three assay points (± SEM). 
Figure 4. Aptamer stabilisation and inhibition of sclerostin function in mammalian 
cells. A.) Stability assay on unmodified Scl 2 aptamers and 3' inverted thymidine 
modified Scl 2 aptamers. B.) Schematic showing the principles behind the reporter 
luciferase activity assay. C.) Effect of 3' inverted thymidine modified sclerostin aptamers 
on Wnt3a mediated activity in MC3T3-E1 cells. Data shown are the mean values of three 
assay points (± SEM). *** represents values statistically significantly different by 
unpaired t-test with 95% confidence. D.) Effect of varying concentrations of 3' inverted 
thymidine modified Scl 2 aptamers against sclerostin function. Data shown are the mean 
values of three assay points (± SEM). 
Figure 5. Aptamer-sclerostin interaction analysis by ITC. Raw calorimetric data and 
binding isotherm of the interaction of aptamers and protein are shown in upper and lower 
panel respectively. A.) ITC analysis of the binding of Scl 2 aptamer to GST-sclerostin. (i) 
Titration of Scl 2 aptamers into PBS buffer. (ii) Titration of Scl 2 aptamer into GST-
sclerostin.   B.) Titration of random sequence into GST-sclerostin.  C.) Titration of Scl 2 
aptamer into GST.  
 
Figure 6. Secondary structure analysis of aptamer structure by CD. A.) CD spectra 
of sclerostin aptamers, 35-mer random sequence and thrombin binding aptamer in PBS. 
B.) CD spectra of Scl 2 aptamer in different buffer conditions. C.) CD melting spectra of 
Scl 2 aptamers.  
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Figure 2 
 
 
 
 
 
 
 
 
 
 
Aptamer clone Core region of the aptamer sequences (5' to 3') No. of 
nucleotides
Percentage
Scl 1
Scl 2
Scl 3
Scl 4
Other Sequences         
** **  ** ****
GTTTCCAAAGCCGGGGGGGTGGGATGGGTT------------ 30         56%
TTGCGCGTTAATTGGGGGGGTGGGTGGGTT------------ 30         24%
TGCCTTGTTATTGTGGTGGGCGGGTGGGAC------------ 30          7%
-----------GGGGGGGGTGGGGTGGGTCAATATTCTCGTC       31          3%   
10%
 18
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3 
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Figure 5 
 
 
 
 
 
 
 
 
 
 
0.0 0.5 1.0 1.5 2.0 2.5
-2.50
-2.00
-1.50
-1.00
-0.50
0.00
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
0.00
0.02
0.04
0 20 40 60 80 100 120 140
C
al
or
ie
s
Time (min)
?
al
/s
ec
Molar Ratio
0.0 0.5 1.0 1.5 2.0
-2.50
-2.00
-1.50
-1.00
-0.50
0.00
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
0.00
0.02
0.04
0 10 20 30 40 50 60 70 80
C
al
or
ie
s
Time (min)
?
al
/s
ec
Molar Ratio
μc
al
/s
ec
0.0 0.5 1.0 1.5 2.0 2.5
-2.50
-2.00
-1.50
-1.00
-0.50
0.00
-0.14
-0.12
-0.10
-0.08
-0.06
-0.04
-0.02
0.00
0.02
0.04
-10 0 10 20 30 40 50 60 70 80 90
Time (min)
?
al
/s
ec
Molar Ratio
C
al
or
ie
s
μc
al
/s
ec
μc
al
/s
ec
A B C
I
II
 21
 
 
 
Figure 6 
0 20 40 60 80 100 120
6
7
8
9
10
11
[
θ ] 
x 
10
-6
(d
eg
-c
m
2 -
m
ol
-1
)
[
θ ] 
x 
10
-6
(d
eg
-c
m
2 -
m
ol
-1
)
[
θ ] 
x 
10
-6
(d
eg
-c
m
2 -
m
ol
-1
)
Temperature oC
A B
C
220 240 260 280 300
-6
-4
-2
0
2
4
6
8
10
12
14
16
Wavelength (nm)
 Scl 1
 Scl 2
 Scl 3
 Scl 4
 Scl 2 InT
 Random sequence
 Thrombin binding aptamer
220 240 260 280 300
-8
-6
-4
-2
0
2
4
6
8
10
12
 
 Scl 2 aptamers in PBS
 Scl 2 aptamers in 10mM Tris-Cl pH7.5, 100mM NaCl
 Scl 2 aptamers in 10mM Tris-Cl pH7.5, 100mM KCl
 Scl 2 aptamers in 10mM Tris-Cl pH7.5, 1mM KCl
 Scl 2 aptamers in 10mM Tris-Cl pH7.5, 1mM EDTA
Wavelength (nm)
